{"id":204089,"date":"2018-04-07T00:07:03","date_gmt":"2018-04-07T00:07:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=204089"},"modified":"2018-04-07T00:07:03","modified_gmt":"2018-04-07T00:07:03","slug":"newly-launched-visiongain-report-global-biosimilar-monoclonal-antibodies-forecast-20182028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/newly-launched-visiongain-report-global-biosimilar-monoclonal-antibodies-forecast-20182028_204089.html","title":{"rendered":"Newly launched Visiongain report: Global Biosimilar Monoclonal Antibodies Forecast 2018-2028"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Biosimilar mAb Market Share by compound by 2028”<\/div>\n<\/div>\n<\/div>\n
Biosimilars MaB Report covers the following; Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab. <\/div>\n

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.<\/p>\n

How this report will benefit you<\/strong>
Read on to discover how you can exploit the future business opportunities emerging in this sector.<\/p>\n

In this brand new 204-page report<\/strong> you will receive 72 tables and 74 figures<\/strong>– all unavailable elsewhere.<\/p>\n

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.<\/p>\n

By ordering and reading our brand new report today you stay better informed and ready to act.<\/p>\n

 <\/p>\n

FRree report overview?<\/p>\n

Please email sara.peerun@visiongain.com or call her on +44 207 5499987<\/p>\n

 <\/p>\n

Report Scope<\/strong><\/p>\n

• Global Biosimilar Monoclonal Antibodies Market forecasts <\/strong>from 2018-2028<\/strong><\/p>\n

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab<\/strong><\/p>\n

• This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
• Remsima\/Inflectra
• Infimab
• Reditux
• BI695500
• CT-P10
• BI695501
• FKB327
• FKB238
• Mabtas
• AcellBia
• Maball
• Clotinab
• Abcixirel
• BCD-022
• BCD-021
• Herzuma
• CANMAB\/Hertraz<\/strong><\/p>\n

 <\/p>\n

Download free sample pages of this report?<\/p>\n

Click here: https:\/\/www.visiongain.com\/Report\/2138\/Global-Biosimilar-Monoclonal-Antibodies-Forecast-2018-2028<\/p>\n

 <\/p>\n

• Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
• The US Biosimilar mAb Market
• Japanese Biosimilar mAb Market
• EU5 Biosimilar mAb Markets
• BRIC and South Korea Biosimilar mAb Markets
• Rest of the World Biosimilar mAb Market<\/strong><\/p>\n

• This report profiles 10 leading companies<\/strong> either with biosimilar mAbs already on the market or in the pipeline<\/p>\n

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market<\/strong><\/p>\n

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.<\/p>\n

 <\/p>\n

Download free sample pages of this report?<\/p>\n

Click here: https:\/\/www.visiongain.com\/Report\/2138\/Global-Biosimilar-Monoclonal-Antibodies-Forecast-2018-2028<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Visiongain Limited
Contact Person:<\/strong> Sara Peerun
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +44 207 3366100
Address:<\/strong>143 Airport House, Purley way
City:<\/strong> London CR0 0XZ
Country:<\/strong> United Kingdom
Website:<\/strong> https:\/\/www.visiongain.com\/Report\/2138\/Global-Biosimilar-Monoclonal-Antibodies-Forecast-2018-2028<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Biosimilar mAb Market Share by compound by 2028” Biosimilars MaB Report covers the following; Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab. The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-204089","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/204089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=204089"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/204089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=204089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=204089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=204089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}